NCT04941404 - A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 10, 2022

Primary Completion Date

July 10, 2023

Study Completion Date

December 31, 2024

Conditions

Glucocorticoid-Refractory aGVHD

Interventions

DRUG

TQ05105 tablets

Participants began oral administration of TQ05105 tablets at 10 mg twice daily (BID),followed by 5 mg or 15 mg BID depending on the situation of the study. twice daily in 28-day cycle until disease progression/intolerance occurs or the sponsor terminates the study.

Trial Locations (4)

215008

The First Affiliated Hospital of Soochow University, Suzhou

300020

Hematology Hospital of the chinese Academy of Medical Sciences, Tianjing

310012

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou

530021

The First Affiliated Hospital of Guangxi Medical University, Nanning